Novel analytical methodologies, real-world data (RWD), innovative trial designs, and new technologies are crucial to optimise ...

The Interministerial Commission for the Pricing of Medicines in Spain has backed access by the Spanish National Health System ...

Unique, patient-focused manufacturing models are needed to scale up innovative cell therapies for cancer and one company, ...

There is huge unmet need for new rare disease therapies, where patients have few or no available options. According to the ...

JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...

"Many loss of pulse incidents happen when the person is alone, leaving them with effectively no chance of receiving ...

Other companies use customer reference and patient data to improve operational agility as they launch and scale their first ...

Artificial intelligence specialist Owkin has added another piece to its medical research portfolio with the launch of ...

US District Judge William Alsup's restraining order has been granted on the grounds that the Office of Personnel Management ...

I envision Chiesi as a proactive leader driving innovation and collaboration within the rare disease community. Our goal is ...

Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement in overall survival.

The 6th TCR-based Therapies Summit returns as the only forum created solely for TCR experts pioneering best-in-class cell- ...